Novartis AG
NVSDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 25, 2025 | $3.99 | 2025-03-12 | 2025-03-12 |
| April 19, 2024 | $3.74 | 2024-03-07 | 2024-03-08 |
| March 20, 2023 | $3.50 | 2023-03-09 | 2023-03-10 |
| March 17, 2022 | $3.33 | 2022-03-08 | 2022-03-09 |
| March 15, 2021 | $3.20 | 2021-03-04 | 2021-03-05 |
Dividends Summary
- Novartis AG has issued 22 dividend payments over the past 21 years
- The most recent dividend was paid 239 days ago, on April 25, 2025
- The highest dividend payed out to investors during this period was $3.99 per share
- The average dividend paid during this period was $2.44 per share.
Company News
Novartis has reached an agreement with the US government to lower innovative medicine prices in the US while supporting continued US manufacturing and R&D investment. The company will launch future medicines with comparable prices across high-income countries, build direct-to-patient platforms for select medicines, and participate in the GENEROUS...
The White House is preparing to announce drug pricing agreements with multiple pharmaceutical companies, aiming to lower prescription drug prices and comply with policy demands from the Trump Administration.
Alnylam Pharmaceuticals, a biotech company focused on RNA interference (RNAi) therapies, has shown significant growth since its 2004 IPO. The company has multiple approved drugs for rare diseases and a promising pipeline of potential treatments across various medical conditions.
Novartis is pioneering radioligand therapy, a targeted cancer treatment that shows promising clinical results. The company estimates the market could reach $25-30 billion, but the technology is still nascent and will take 10-15 years to become mainstream.
Incyte Corporation is expected to report strong Q2 2024 earnings, driven by increased sales of its lead drug Jakafi and other newly approved drugs. The company's earnings are likely to benefit from higher royalties from Novartis for the commercialization of Jakafi in ex-U.S. markets.
